Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

NEW YORK — Tempus said on Wednesday that its cancer biomarker alliance with Bristol Myers Squibb has been expanded to include RNA-based targets.

According to Tempus, it has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new biomarkers related to undisclosed cancer subtypes. Under the expanded deal, Bristol Myers Squibb has licensed from Tempus terabytes of additional data cohorts across multiple tumor types, which will be analyzed with a focus on RNA expression targets.

Additional terms were not disclosed.

"Our work with Bristol Myers Squibb has made it possible to transform terabytes of data into clinically relevant insight by stratifying diseases into key molecular subtypes and uncovering potentially better ways to treat patients going forward," Tempus Chief Operating Officer Ryan Fukushima said in a statement.

In December, Chicago-based Tempus raised $200 million in a new Series G2 financing round and announced an oncology testing alliance with Bayer.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.